1b) Don't miss @BrianHill_MDPhD's companion update from #ASH on mantle cell #lymphoma #MCL, posted this morning starting at https://t.co/RmzdEemHXG and now also available at https://t.co/UucJAnFScj
— @onc_ce (@onc_ce) December 21, 2023
3) Lots of 🆕 data on #FL at #ASH23! We'll hit the highlights in this review. You shoulda been there! pic.twitter.com/Gv9v2XV1hr
— @onc_ce (@onc_ce) December 21, 2023
4b) Other extranodal involvement is infrequent, as are constitutional symptoms of (fever, night sweats, weight loss). #Cytopenias may occur. Dx is best established by incisional #biopsy & #IHC staining.
— @onc_ce (@onc_ce) December 21, 2023
5a) Cases of #FL are risk-stratified by the Follicular Lymphoma International Prognostic Index (#FLIPI), w/ 5 independent predictors of ⬇️survival:
— @onc_ce (@onc_ce) December 21, 2023
👉age >60y
👉hemoglobin <12 g/dL
👉⬆️serum LDH
👉 Ann Arbor stage III/IV
👉 >4 involved nodal areas.
5c) In fact, no #OS advantage for early treatment by chemotx or single-agent #rituximab.
— @onc_ce (@onc_ce) December 21, 2023
If tx needed, predom approach is #chemoimmunotherapy ➡️ ⬆️#ORR #DOR #OS.
5e) R-CHOP appropriate if transformation or aggressive disease is suspected, such as high LDH and/or SUVs >18 on staging PET scan
— @onc_ce (@onc_ce) December 21, 2023
See 🔓 https://t.co/cEVUGLTHso
6a) For relapsed/refractory disease, historically stem cell transplantation (#SCT) has been used. Other options include the #EZH2 inhibitor, #Tazemetostat
— @onc_ce (@onc_ce) December 21, 2023
See 🔓https://t.co/14dxZmjfJC
6c) Toxicities such as cytokine release syndrome #CRS tend to be manageable and low grade.https://t.co/o0cwrLaVK6
— @onc_ce (@onc_ce) December 21, 2023
7a) Further on the #CAR_T front, we had new data presented at #ASH23: reported results of #TRANSCEND_FL. pic.twitter.com/JuyB7Dsvsr
— @onc_ce (@onc_ce) December 21, 2023
7c) These were high-risk pts, required to have dz progression within 24mos following tx received no longer than 6mos after original dx, high tumor burden as defined by #mGELF criteria, or both. All pts had received 1 prior combo of systemic tx + anti-CD20 antibody & alkylator.
— @onc_ce (@onc_ce) December 21, 2023
7e) You can watch a brief 📽️of Prof Morschhauser summarizing these data at🔓https://t.co/dH6QaRUndy.
— @onc_ce (@onc_ce) December 21, 2023
The data may support liso-cel's expansion to treating earlier line patients with high-risk disease. Longer f/u remains to be done to see how the therapy fares in the long term. pic.twitter.com/khewh7uh9M
8b) In this study, N=40; CMR=81.5%; ≥1 grade 3 or 4 TEAE=43.2%. #lymsm #lymphoma pic.twitter.com/b0XE3KfalS
— @onc_ce (@onc_ce) December 21, 2023
9b) This study suggests high efficacy of #mosunetuzumab SC in 1L for these patients
— @onc_ce (@onc_ce) December 21, 2023
👉 Fixed duration
👉#ORR of 96%, with 76% achieving #CR
👉Manageable toxicity profile
👉Notable: 3 CD20neg relapses
🗓️ Longer follow-up needed pic.twitter.com/vOIf1XAFDi
10b) Updated data after 3 years of follow-up were shared at #ASH23.
— @onc_ce (@onc_ce) December 21, 2023
👉N=90
👉30-month #DOR=72.7%
👉3-year #OS=82%
🛟 The safety profile was manageable with no new AEs reported. #lymphoma #lymsm #leusm pic.twitter.com/Tu7cYsEphp
11b) #Epcoritamab in R/R #FL
— @onc_ce (@onc_ce) December 21, 2023
👉128 pts, all 2+ prior LOT
👉42% #POD24
👉#ORR 82% (#CR 63%)
🗓️median time to response 1.4 mos
🗓️mPFS 15.4 mos (74% of CRs sustained @ 18 mos)
👉 MRD negativity➡️PFS
👉10% fatal #TEAEs???
👉Indefinite therapy req'd pic.twitter.com/nsCzFcPhbq
12b) It was c, #lisocabtagene maraleucel (#liso_cel), in the #TRANSCEND_FL trial presented at #ASH23.
— @onc_ce (@onc_ce) December 21, 2023
Now, which drug combined with #mosunetuzumab showed 89% #CR and 92% #ORR for 1L management of #FL?
13) And that's MY picks from among the many #FL highlights from #ASH23. Go forth now and claim your 0.5hr 🆓 CE/#CME at https://t.co/6sledu8Rrh, and FOLLOW US here at @onc_ce for more #hemonc #MedEd! Thanks to @BrianHill_MDPhD.#lymphomasm #OncTwitter
— @onc_ce (@onc_ce) December 21, 2023